Pfizer’s BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
NEW YORK, October 20, 2025 — Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic […]
